Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB–D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915
Georgina V. Long(The University of Sydney), Jeffrey S. Weber(NYU Langone Health), Jonathan Baden(Bristol-Myers Squibb (United States)), Shu‐Pang Huang(Bristol-Myers Squibb (United States)), Daniel J. Tenney(Bristol-Myers Squibb (Germany)), Gina Fusaro(Bristol-Myers Squibb (United States)), Hao Tang(Stanford Health Care), David Balli, James Larkin(Trinity College Dublin), Corey Ritchings(Bristol-Myers Squibb (United States)), Keyur Desai(Bristol-Myers Squibb (United States)), Han Chang(Bristol-Myers Squibb (United States)), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Sheen Wang(Bristol-Myers Squibb (United States)), Sonia Dolfi(Bristol-Myers Squibb (United States))
Cited by 11
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2019|3.7k